{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T13:02:50Z","timestamp":1793278970708,"version":"4.5.0"},"reference-count":138,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006451","name":"Hospices Civils de Lyon","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006451","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Considerable progress has been made in the management of cancer patients in the last decade with the arrival of anti-cancer immunotherapies (immune checkpoint inhibitors) and targeted therapies. As a result, a broad spectrum of cancers, not just hormone-sensitive ones, have seen several patients achieve profound and prolonged remissions, or even cures. The management of medium- and long-term side-effects of treatment and quality of life of patients are essential considerations. This is especially true for bone, as bone fragility can lead to increased fractures and loss of autonomy, ultimately reducing the possibility of resuming physical activity. Physical activity is essential for lasting oncological remission and prevention of fatigue. While the issue of hormone therapies and their association with breast cancer has been recognized for some time, the situation is relatively new with regards to targeted therapies and immunotherapies. This is particularly challenging given the wide range of available targeted therapies and their application to numerous cancer types. This article provides a comprehensive review of the bone effects of the main anti-cancer therapies currently in use. The review goes beyond glucocorticoids and hormone therapies and discusses for each drug category what is known regarding cellular effects, BMD effects, and fracture incidence.<\/jats:p>","DOI":"10.1007\/s00223-025-01362-0","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T02:51:06Z","timestamp":1743303066000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Bone Effects of Anti-Cancer Treatments in 2024"],"prefix":"10.1007","volume":"116","author":[{"given":"Marie","family":"Teissonni\u00e8re","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Point","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Biver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peyman","family":"Hadji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Bonnelye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Ebeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"de Villiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerold","family":"Holzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Body","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada El Hajj","family":"Fuleihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Rizzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9318-6785","authenticated-orcid":false,"given":"Cyrille B.","family":"Confavreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"issue":"6","key":"1362_CR1","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/annonc\/mdz120","volume":"30","author":"G Marcucci","year":"2019","unstructured":"Marcucci G, Beltrami G, Tamburini A, Body JJ, Confavreux CB, Hadji P et al (2019) Bone health in childhood cancer: review of the literature and recommendations for the management of bone health in childhood cancer survivors. Ann Oncol 30(6):908\u2013920","journal-title":"Ann Oncol"},{"issue":"4","key":"1362_CR2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11914-013-0165-0","volume":"11","author":"CL Wilson","year":"2013","unstructured":"Wilson CL, Ness KK (2013) Bone mineral density deficits and fractures in survivors of childhood cancer. Curr Osteoporos Rep 11(4):329\u2013337","journal-title":"Curr Osteoporos Rep"},{"issue":"22","key":"1362_CR3","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.3390\/cancers13225711","volume":"13","author":"CB Confavreux","year":"2021","unstructured":"Confavreux CB, Follet H, Mitton D, Pialat JB, Cl\u00e9zardin P (2021) Fracture Risk Evaluation of Bone Metastases: A Burning Issue. Cancers (Basel) 13(22):5711","journal-title":"Cancers (Basel)"},{"issue":"2","key":"1362_CR4","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nrrheum.2014.188","volume":"11","author":"R Rizzoli","year":"2015","unstructured":"Rizzoli R, Biver E (2015) Glucocorticoid-induced osteoporosis: who to treat with what agent? Nat Rev Rheumatol 11(2):98\u2013109","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"1362_CR5","doi-asserted-by":"crossref","first-page":"luac006","DOI":"10.1210\/jcemcr\/luac006","volume":"1","author":"K Subbu","year":"2023","unstructured":"Subbu K, Renner JB, Rubin JE (2023) Extensive osteonecrosis after glucocorticoids: clinical response to bisphosphonate. JCEM Case Rep 1(1):luac006","journal-title":"JCEM Case Rep"},{"issue":"10","key":"1362_CR6","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00198-007-0394-0","volume":"18","author":"E Canalis","year":"2007","unstructured":"Canalis E, Mazziotti G, Giustina A, Bilezikian JP (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18(10):1319\u20131328","journal-title":"Osteoporos Int"},{"issue":"13","key":"1362_CR7","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s001980200108","volume":"70","author":"T Van Staa","year":"2002","unstructured":"Van Staa T, Leukfens H, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 70(13):777\u2013787","journal-title":"Osteoporos Int"},{"issue":"6","key":"1362_CR8","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","volume":"15","author":"TP Van Staa","year":"2000","unstructured":"Van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15(6):993\u20131000","journal-title":"J Bone Miner Res"},{"issue":"6","key":"1362_CR9","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1359\/JBMR.040134","volume":"19","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton LJ III et al (2004) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19(6):893\u2013899","journal-title":"J Bone Miner Res"},{"key":"1362_CR10","doi-asserted-by":"crossref","first-page":"103492","DOI":"10.1016\/j.critrevonc.2021.103492","volume":"168","author":"L Velentza","year":"2021","unstructured":"Velentza L, Zaman F, S\u00e4vendahl L (2021) Bone health in glucocorticoid-treated childhood acute lymphoblastic leukemia. Crit Rev Oncol\/Hematol 168:103492","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"9","key":"1362_CR11","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1056\/NEJMoa040367","volume":"351","author":"MB Leonard","year":"2004","unstructured":"Leonard MB, Feldman HI, Shults J, Zemel BS, Foster BJ, Stallings VA (2004) Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome. N Engl J Med 351(9):868\u2013875","journal-title":"N Engl J Med"},{"issue":"3","key":"1362_CR12","doi-asserted-by":"crossref","first-page":"e705","DOI":"10.1542\/peds.2007-1396","volume":"121","author":"K Wasilewski-Masker","year":"2008","unstructured":"Wasilewski-Masker K, Kaste SC, Hudson MM, Esiashvili N, Mattano LA, Meacham LR (2008) Bone mineral density deficits in survivors of childhood cancer: long-term follow-up guidelines and review of the literature. Pediatrics 121(3):e705\u2013e713","journal-title":"Pediatrics"},{"key":"1362_CR13","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1038\/boneres.2017.13","volume":"5","author":"EE Beier","year":"2017","unstructured":"Beier EE, Sheu TJ, Resseguie EA, Takahata M, Awad HA, Cory-Slechta DA et al (2017) Sclerostin activity plays a key role in the negative effect of glucocorticoid signaling on osteoblast function in mice. Bone Res 5:17013","journal-title":"Bone Res"},{"issue":"2","key":"1362_CR14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbrc.2015.02.161","volume":"460","author":"H Ding","year":"2015","unstructured":"Ding H, Wang T, Xu D, Cha B, Liu J, Li Y (2015) Dexamethasone-induced apoptosis of osteocytic and osteoblastic cells is mediated by TAK1 activation. Biochem Biophys Res Commun 460(2):157\u2013163","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"1362_CR15","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1056\/NEJMra050776","volume":"354","author":"JD Yager","year":"2006","unstructured":"Yager JD, Davidson NE (2006) Estrogen carcinogenesis in breast cancer. N Engl J Med 354(3):270\u2013282","journal-title":"N Engl J Med"},{"issue":"3","key":"1362_CR16","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1007\/s12282-020-01205-w","volume":"28","author":"J Kurebayashi","year":"2021","unstructured":"Kurebayashi J, Shiba E, Toyama T, Matsumoto H, Okazaki M, Nomizu T (2021) A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer. Breast Cancer 28(3):684\u2013697","journal-title":"Breast Cancer"},{"issue":"3","key":"1362_CR17","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/jnci\/djab213","volume":"114","author":"M Lambertini","year":"2021","unstructured":"Lambertini M, Boni L, Michelotti A, Magnolfi E, Cogoni AA, Mosconi AM et al (2021) Long-term outcomes with pharmacological ovarian suppression during chemotherapy in premenopausal early breast cancer patients. J Natl Cancer Inst 114(3):400\u2013408","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"1362_CR18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.clgc.2012.08.005","volume":"11","author":"S Ziaran","year":"2013","unstructured":"Ziaran S, Goncalves FM, Sn JB (2013) Complex metabolic and skeletal changes in men taking long-term androgen deprivation therapy. Clin Genitourin Cancer 11(1):33\u201338","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"1362_CR19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.eururo.2020.06.002","volume":"79","author":"M Abufaraj","year":"2021","unstructured":"Abufaraj M, Iwata T, Kimura S, Haddad A, Al-Ani H, Abusubaih L et al (2021) Differential impact of gonadotropin-releasing hormone antagonist versus agonist on clinical safety and oncologic outcomes on patients with metastatic prostate cancer: a meta-analysis of randomized controlled trials. Eur Urol 79(1):44\u201353","journal-title":"Eur Urol"},{"issue":"1","key":"1362_CR20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jbspin.2018.09.017","volume":"86","author":"K Briot","year":"2019","unstructured":"Briot K, Paccou J, Beuzeboc P, Bonneterre J, Bouvard B, Confavreux CB et al (2019) French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation. Joint Bone Spine 86(1):21\u201328","journal-title":"Joint Bone Spine"},{"issue":"2","key":"1362_CR21","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","volume":"352","author":"VB Shahinian","year":"2005","unstructured":"Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352(2):154\u2013164","journal-title":"N Engl J Med"},{"issue":"4","key":"1362_CR22","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1046\/j.1464-410X.2000.00774.x","volume":"86","author":"T Hatano","year":"2000","unstructured":"Hatano T, Oishi Y, Furuta A, Iwamuro S, Tashiro K (2000) Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int 86(4):449\u2013452","journal-title":"BJU Int"},{"issue":"10","key":"1362_CR23","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.2174\/1871530321666201216164410","volume":"21","author":"NV Mohamad","year":"2023","unstructured":"Mohamad NV, Ima-Nirwana S, Chin KY (2023) The skeletal effects of gonadotropin-releasing hormone antagonists: a concise review. Endocr, Metab Immune Disord - Drug Targets 21(10):1713\u20131720","journal-title":"Endocr, Metab Immune Disord - Drug Targets"},{"issue":"3","key":"1362_CR24","doi-asserted-by":"crossref","first-page":"R111","DOI":"10.1530\/JOE-19-0077","volume":"241","author":"SK Ramchand","year":"2019","unstructured":"Ramchand SK, Cheung YM, Yeo B, Grossmann M (2019) The effects of adjuvant endocrine therapy on bone health in women with breast cancer. J Endocrinol 241(3):R111\u2013R124","journal-title":"J Endocrinol"},{"issue":"5","key":"1362_CR25","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jbspin.2019.07.005","volume":"86","author":"B Bouvard","year":"2019","unstructured":"Bouvard B, Confavreux CB, Briot K, Bonneterre J, Cormier C, Cortet B et al (2019) French recommendations on strategies for preventing and treating osteoporosis induced by adjuvant breast cancer therapies. Joint Bone Spine 86(5):542\u2013553","journal-title":"Joint Bone Spine"},{"key":"1362_CR26","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mdq541","volume":"22","author":"R Eastell","year":"2011","unstructured":"Eastell R, Adams J, Clack G, Howell A, Cuzick J, Mackey J et al (2011) Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. Ann Oncol 22:857\u2013862","journal-title":"Ann Oncol"},{"issue":"1","key":"1362_CR27","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.urology.2004.03.012","volume":"64","author":"Y Miyaji","year":"2004","unstructured":"Miyaji Y, Saika T, Yamamoto Y, Kusaka N, Arata R, Ebara S et al (2004) Effects of gonadotropin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer. Urology 64(1):128\u2013131","journal-title":"Urology"},{"issue":"1","key":"1362_CR28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0090-4295(02)02006-X","volume":"61","author":"MR Smith","year":"2003","unstructured":"Smith MR, Fallon MA, Goode MJ (2003) Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer. Urology 61(1):127\u2013131","journal-title":"Urology"},{"issue":"3","key":"1362_CR29","first-page":"1286","volume":"25","author":"A Bargiota","year":"2020","unstructured":"Bargiota A, Oeconomou A, Zachos I, Samarinas M, Pisters LL, Tzortzis V (2020) Adverse effects of androgen deprivation therapy in patients with prostate cancer: focus on muscle and bone health. J BUON 25(3):1286\u20131294","journal-title":"J BUON"},{"issue":"1","key":"1362_CR30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, de Santana P, Gomes AJ, Given R et al (2019) Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 381(1):13\u201324","journal-title":"N Engl J Med"},{"issue":"32","key":"1362_CR31","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A et al (2019) ARCHES: a randomized, phase iii study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol 37(32):2974\u20132986","journal-title":"J Clin Oncol"},{"issue":"8","key":"1362_CR32","doi-asserted-by":"crossref","first-page":"T39","DOI":"10.1530\/ERC-21-0118","volume":"28","author":"W Bouleftour","year":"2021","unstructured":"Bouleftour W, Boussoualim K, Sotton S, Vassal C, Thomas T, Magne N et al (2021) Second-generation hormonotherapy in prostate cancer and bone microenvironment. Endocr.-Related Cancer 28(8):T39-49","journal-title":"Endocr.-Related Cancer"},{"issue":"13","key":"1362_CR33","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","volume":"380","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S et al (2019) Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 380(13):1235\u20131246","journal-title":"N Engl J Med"},{"key":"1362_CR34","doi-asserted-by":"crossref","first-page":"652979","DOI":"10.3389\/fphar.2021.652979","volume":"12","author":"CC Wu","year":"2021","unstructured":"Wu CC, Chen PY, Wang SW, Tsai MH, Wang YCL, Tai CL et al (2021) Risk of fracture during androgen deprivation therapy among patients with prostate cancer: a systematic review and meta-analysis of cohort studies. Front Pharmacol 12:652979","journal-title":"Front Pharmacol"},{"issue":"104","key":"1362_CR35","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/j.1464-410X.2009.08458.x","volume":"6","author":"A Spry","year":"2009","unstructured":"Spry A, Galv\u00e3o S, Davies R, La Bianca S, Joseph D, Davdison A (2009) Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-months observation study. BJU Int 6(104):806\u2013812","journal-title":"BJU Int"},{"issue":"3","key":"1362_CR36","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.tem.2020.12.004","volume":"32","author":"AM Formenti","year":"2021","unstructured":"Formenti AM, Dalla Volta A, di Filippo L, Berruti A, Giustina A (2021) Effects of medical treatment of prostate cancer on bone health. Trends Endocrinol & Metab 32(3):135\u2013158","journal-title":"Trends Endocrinol & Metab"},{"issue":"4","key":"1362_CR37","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/sj.pcan.4500599","volume":"5","author":"DM Preston","year":"2002","unstructured":"Preston DM, Torr\u00e9ns JI, Harding P, Howard RS, Duncan WE, McLeod DG (2002) Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss. Prostate Cancer Prostatic Dis 5(4):304\u2013310","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"12","key":"1362_CR38","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1111\/j.1464-410X.2010.09726.x","volume":"107","author":"VK Wadhwa","year":"2011","unstructured":"Wadhwa VK, Weston R, Parr NJ (2011) Bicalutamide monotherapy preserves bone mineral density, muscle strength and has significant health-related quality of life benefits for osteoporotic men with prostate cancer. BJU Int 107(12):1923\u20131929","journal-title":"BJU Int"},{"key":"1362_CR39","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.canlet.2021.10.042","volume":"525","author":"S Su","year":"2022","unstructured":"Su S, Cao J, Meng X, Liu R, Vander Ark A, Woodford E et al (2022) Enzalutamide-induced and PTH1R-mediated TGFBR2 degradation in osteoblasts confers resistance in prostate cancer bone metastases. Cancer Lett 525:170\u2013178","journal-title":"Cancer Lett"},{"issue":"22","key":"1362_CR40","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/jnci\/dji372","volume":"97","author":"B Fisher","year":"2005","unstructured":"Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A et al (2005) Tamoxifen for the prevention of breast cancer: current status of the national surgical adjuvant breast and bowel project P-1 study. JNCI: J National Cancer Inst 97(22):1652\u20131662","journal-title":"JNCI: J National Cancer Inst"},{"issue":"5","key":"1362_CR41","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s00223-008-9132-7","volume":"82","author":"P Vestergaard","year":"2008","unstructured":"Vestergaard P, Rejnmark L, Mosekilde L (2008) Effect of tamoxifen and aromatase inhibitors on the risk of fractures in women with breast cancer. Calcif Tissue Int 82(5):334\u2013340","journal-title":"Calcif Tissue Int"},{"key":"1362_CR42","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1359\/jbmr.060508","volume":"21","author":"R Eastell","year":"2006","unstructured":"Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE et al (2006) Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 21:1215\u20131223","journal-title":"J Bone Miner Res"},{"issue":"11","key":"1362_CR43","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1007\/s00198-018-4642-2","volume":"29","author":"I Kyvernitakis","year":"2018","unstructured":"Kyvernitakis I, Kostev K, Hadji P (2018) The tamoxifen paradox-influence of adjuvant tamoxifen on fracture risk in pre- and postmenopausal women with breast cancer. Osteoporos Int 29(11):2557\u20132564","journal-title":"Osteoporos Int"},{"issue":"326","key":"1362_CR44","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJM199203263261302","volume":"26","author":"RR Love","year":"1992","unstructured":"Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC et al (1992) Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 26(326):852\u2013856","journal-title":"N Engl J Med"},{"key":"1362_CR45","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.1996.14.1.78","volume":"14","author":"TJ Powles","year":"1996","unstructured":"Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S (1996) Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14:78\u201384","journal-title":"J Clin Oncol"},{"issue":"2","key":"1362_CR46","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2174\/1574884711308020006","volume":"8","author":"PY Maximov","year":"2013","unstructured":"Maximov PY, Lee TM, Jordan VC (2013) The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr Clin Pharmacol 8(2):135\u2013155","journal-title":"Curr Clin Pharmacol"},{"key":"1362_CR47","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1200\/JCO.2004.08.148","volume":"22","author":"A Sverrisdottir","year":"2004","unstructured":"Sverrisdottir A, Fornander T, Jacobsson H, von Schoultz E, Rutqvist LE (2004) Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol 22:3694\u20133699","journal-title":"J Clin Oncol"},{"issue":"18","key":"1362_CR48","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.breast.2009.03.003","volume":"3","author":"P Hadji","year":"2009","unstructured":"Hadji P, Ziller M, Kieback D, Menschik T, Kalder M, Kuck J (2009) The effect of exemestane or tamoxifen on markers on bone turnover\u202f: results of a German sub-study of the tamoxifen exemestane adjuvant multicentre (TEAM) trial. Breast 3(18):159\u2013164","journal-title":"Breast"},{"key":"1362_CR49","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1159\/000323489","volume":"79","author":"T Aihara","year":"2010","unstructured":"Aihara T, Suemasu K, Takei H, Hozumi Y, Takehara M, Saito T et al (2010) Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy. Oncology 79:376\u2013381","journal-title":"Oncology"},{"key":"1362_CR50","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1016\/j.ejca.2007.08.029","volume":"43","author":"EV McCloskey","year":"2007","unstructured":"McCloskey EV, Hannon RA, Lakner G, Fraser WD, Clack G, Miyamoto A et al (2007) Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. Eur J Cancer 43:2523\u20132531","journal-title":"Eur J Cancer"},{"key":"1362_CR51","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(05)74803-0","volume":"365","author":"A Howell","year":"2005","unstructured":"Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer. Lancet 365:60\u201362","journal-title":"Lancet"},{"issue":"2","key":"1362_CR52","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1470-2045(07)70003-7","volume":"8","author":"RE Coleman","year":"2007","unstructured":"Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J et al (2007) Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 8(2):119\u2013127","journal-title":"Lancet Oncol"},{"key":"1362_CR53","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/annonc\/mdp033","volume":"20","author":"M Rabaglio","year":"2009","unstructured":"Rabaglio M, Sun Z, Price KN, Castiglione-Gertsch M, Hawle H, Thurlimann B et al (2009) Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1\u201398 trial. Ann Oncol 20:1489\u20131498","journal-title":"Ann Oncol"},{"key":"1362_CR54","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0140-6736(05)67059-6","volume":"366","author":"R Jakesz","year":"2005","unstructured":"Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C et al (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years\u2019 adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455\u2013462","journal-title":"Lancet"},{"key":"1362_CR55","doi-asserted-by":"crossref","unstructured":"Arimidex, Tamoxifen, Alone or in Combination Trialists\u2019 Group, Buzdar A, Howell A, Cuzick J, Wale C, Distler W, et al. (2006). Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. 7(8): 633\u201143.","DOI":"10.1016\/S1470-2045(06)70767-7"},{"issue":"5","key":"1362_CR56","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1200\/JCO.2006.08.8617","volume":"25","author":"AS Coates","year":"2007","unstructured":"Coates AS, Keshaviah A, Th\u00fcrlimann B, Mouridsen H, Mauriac L, Forbes JF et al (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1\u201398. J Clin Oncol 25(5):486\u2013492","journal-title":"J Clin Oncol"},{"key":"1362_CR57","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/jnci\/djm246","volume":"99","author":"R Jakesz","year":"2007","unstructured":"Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E et al (2007) Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian breast and colorectal cancer study group trial 6a. J Natl Cancer Inst 99:1845\u20131853","journal-title":"J Natl Cancer Inst"},{"issue":"9561","key":"1362_CR58","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0140-6736(07)60200-1","volume":"369","author":"RC Coombes","year":"2007","unstructured":"Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE et al (2007) Survival and safety of exemestane versus tamoxifen after 2\u20133 years\u2019 tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369(9561):559\u2013570","journal-title":"Lancet"},{"key":"1362_CR59","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/jnci\/dji250","volume":"97","author":"PE Goss","year":"2005","unstructured":"Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ et al (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262\u20131271","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"1362_CR60","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/bjc.2016.314","volume":"115","author":"E Colzani","year":"2016","unstructured":"Colzani E, Clements M, Johansson ALV, Liljegren A, He W, Brand J et al (2016) Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study. Br J Cancer 115(11):1400\u20131407","journal-title":"Br J Cancer"},{"key":"1362_CR61","doi-asserted-by":"crossref","unstructured":"Arimidex TA or in CTG, Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, et al. (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 9: 45\u201153.","DOI":"10.1016\/S1470-2045(07)70385-6"},{"issue":"11","key":"1362_CR62","first-page":"562","volume":"32","author":"KJ Jerzak","year":"2018","unstructured":"Jerzak KJ, Raphael J, Desautels DN, Blanchette PS, Tyono I, Pritchard KI (2018) Bone-targeted therapy in early breast cancer. Oncology (Williston Park) 32(11):562\u2013569","journal-title":"Oncology (Williston Park)"},{"key":"1362_CR63","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S1470-2045(14)70035-X","volume":"15","author":"PE Goss","year":"2014","unstructured":"Goss PE, Hershman DL, Cheung AM, Ingle JN, Khosla S, Stearns V et al (2014) Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial. Lancet Oncol 15:474\u2013482","journal-title":"Lancet Oncol"},{"key":"1362_CR64","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx141","author":"H Goldvaser","year":"2018","unstructured":"Goldvaser H, Barnes TA, \u0160eruga B, Cescon DW, Oca\u00f1a A, Ribnikar D et al (2018) Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djx141","journal-title":"J Natl Cancer Inst"},{"key":"1362_CR65","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1200\/JCO.2005.05.4882","volume":"24","author":"EA Perez","year":"2006","unstructured":"Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP et al (2006) Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 24:3629\u20133635","journal-title":"J Clin Oncol"},{"key":"1362_CR66","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10549-014-2849-2","volume":"144","author":"A Decensi","year":"2014","unstructured":"Decensi A, Sun Z, Guerrieri-Gonzaga A, Thurlimann B, McIntosh C, Tondini C et al (2014) Bone mineral density and circulating biomarkers in the BIG 1\u201398 trial comparing adjuvant letrozole, tamoxifen and their sequences. Breast Cancer Res Treat 144:321\u2013329","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"1362_CR67","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.bone.2007.06.004","volume":"41","author":"CB Confavreux","year":"2007","unstructured":"Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD (2007) Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prev Bisphosphonates Bone 41(3):346\u2013352","journal-title":"Prev Bisphosphonates Bone"},{"issue":"26","key":"1362_CR68","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.2007.11.0726","volume":"7","author":"R Eastell","year":"2008","unstructured":"Eastell R, Adams J, Coleman R, Howell A, Hannon R, Cuzick J (2008) Effect of anastrozole on bone mineral density: 5-years results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 7(26):1051\u20131057","journal-title":"J Clin Oncol"},{"key":"1362_CR69","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1200\/JCO.2012.44.7805","volume":"31","author":"PE Goss","year":"2013","unstructured":"Goss PE, Ingle JN, Pritchard KI, Ellis MJ, Sledge GW, Budd GT et al (2013) Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27\u2013a randomized controlled phase III trial. J Clin Oncol 31:1398\u20131404","journal-title":"J Clin Oncol"},{"key":"1362_CR70","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.bone.2003.11.006","volume":"34","author":"PE Goss","year":"2004","unstructured":"Goss PE, Qi S, Josse RG, Pritzker KP, Mendes M, Hu H et al (2004) The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. Bone 34:384\u2013392","journal-title":"Bone"},{"key":"1362_CR71","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1470-2045(11)70389-8","volume":"13","author":"AM Cheung","year":"2012","unstructured":"Cheung AM, Tile L, Cardew S, Pruthi S, Robbins J, Tomlinson G et al (2012) Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. Lancet Oncol 13:275\u2013284","journal-title":"Lancet Oncol"},{"issue":"11","key":"1362_CR72","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1007\/s00198-011-1870-0","volume":"23","author":"R Rizzoli","year":"2012","unstructured":"Rizzoli R, Body JJ, DeCensi A, De Censi A, Reginster JY, Piscitelli P et al (2012) Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper. Osteoporos Int 23(11):2567\u20132576","journal-title":"Osteoporos Int"},{"issue":"7","key":"1362_CR73","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.arcmed.2014.10.007","volume":"45","author":"G Su","year":"2014","unstructured":"Su G, Xiang Y, He G, Jiang C, Li C, Yan Z et al (2014) Bisphosphonates may protect against bone loss in postmenopausal women with early breast cancer receiving adjuvant aromatase inhibitor therapy: results from a meta-analysis. Arch Med Res 45(7):570\u2013579","journal-title":"Arch Med Res"},{"key":"1362_CR74","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bone.2018.06.007","volume":"114","author":"I Kyvernitakis","year":"2018","unstructured":"Kyvernitakis I, Kann PH, Thomasius F, Hars O, Hadji P (2018) Prevention of breast cancer treatment-induced bone loss in premenopausal women treated with zoledronic acid: final 5-year results from the randomized, double-blind, placebo-controlled ProBONE II trial. Bone 114:109\u2013115","journal-title":"Bone"},{"key":"1362_CR75","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2005.02.7102","volume":"25","author":"MF Gnant","year":"2007","unstructured":"Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M et al (2007) Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian breast and colorectal cancer study group. J Clin Oncol 25:820\u2013828","journal-title":"J Clin Oncol"},{"issue":"2","key":"1362_CR76","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mds277","volume":"24","author":"R Coleman","year":"2013","unstructured":"Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P et al (2013) Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol 24(2):398\u2013405","journal-title":"Ann Oncol"},{"issue":"5","key":"1362_CR77","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/cncr.26313","volume":"118","author":"AM Brufsky","year":"2012","unstructured":"Brufsky AM, Harker WG, Beck JT, Bosserman L, Vogel C, Seidler C et al (2012) Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 118(5):1192\u20131201","journal-title":"Cancer"},{"issue":"30","key":"1362_CR78","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","volume":"26","author":"GK Ellis","year":"2008","unstructured":"Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J et al (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26(30):4875\u20134882","journal-title":"J Clin Oncol"},{"issue":"1","key":"1362_CR79","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10549-009-0352-y","volume":"118","author":"GK Ellis","year":"2009","unstructured":"Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Fan M et al (2009) Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. Breast Cancer Res Treat 118(1):81\u201387","journal-title":"Breast Cancer Res Treat"},{"key":"1362_CR80","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","volume":"386","author":"M Gnant","year":"2015","unstructured":"Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R et al (2015) Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 386:433\u2013443","journal-title":"Lancet"},{"issue":"10001","key":"1362_CR81","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","volume":"386","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2015","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (2015) Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 386(10001):1353\u20131361","journal-title":"Lancet"},{"issue":"6","key":"1362_CR82","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","volume":"169","author":"MR Smith","year":"2003","unstructured":"Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N (2003) Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169(6):2008\u20132012","journal-title":"J Urol"},{"issue":"3","key":"1362_CR83","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.juro.2006.04.078","volume":"176","author":"CW Ryan","year":"2006","unstructured":"Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV (2006) Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol 176(3):972\u2013978","journal-title":"J Urol"},{"issue":"9","key":"1362_CR84","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","volume":"25","author":"MD Michaelson","year":"2007","unstructured":"Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA et al (2007) Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 25(9):1038\u20131042","journal-title":"J Clin Oncol"},{"issue":"5","key":"1362_CR85","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/j.juro.2009.07.046","volume":"182","author":"N Bhoopalam","year":"2009","unstructured":"Bhoopalam N, Campbell SC, Moritz T, Broderick WR, Iyer P, Arcenas AG et al (2009) Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy. J Urol 182(5):2257\u20132264","journal-title":"J Urol"},{"issue":"6","key":"1362_CR86","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7326\/0003-4819-146-6-200703200-00006","volume":"146","author":"SL Greenspan","year":"2007","unstructured":"Greenspan SL, Nelson JB, Trump DL, Resnick NM (2007) Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 146(6):416\u2013424","journal-title":"Ann Intern Med"},{"issue":"11","key":"1362_CR87","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1111\/j.1464-410X.2009.08622.x","volume":"104","author":"J Planas","year":"2009","unstructured":"Planas J, Trilla E, Ravent\u00f3s C, Cecchini L, Orsola A, Salvador C et al (2009) Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis. BJU Int 104(11):1637\u20131640","journal-title":"BJU Int"},{"key":"1362_CR88","doi-asserted-by":"crossref","unstructured":"Klotz LH, McNeill IY, Kebabdjian M, Zhang L, Chin JL, Canadian Urology Research Consortium. (2013). A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study. Eur Urol. 63(5):927\u201135.","DOI":"10.1016\/j.eururo.2012.09.007"},{"issue":"12","key":"1362_CR89","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","volume":"31","author":"R Coleman","year":"2020","unstructured":"Coleman R, Hadji P, Body JJ, Santini D, Chow E, Terpos E et al (2020) Bone health in cancer: ESMO clinical practice guidelines\u2020. Ann Oncol 31(12):1650\u20131663","journal-title":"Ann Oncol"},{"key":"1362_CR90","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010816.pub2","author":"K Scott","year":"2016","unstructured":"Scott K, Hayden PJ, Will A, Wheatley K, Coyne I (2016) Bortezomib for the treatment of multiple myeloma. Cochrane Database Systematic Rev [Internet]. https:\/\/doi.org\/10.1002\/14651858.CD010816.pub2","journal-title":"Cochrane Database Systematic Rev [Internet]"},{"issue":"1","key":"1362_CR91","first-page":"13","volume":"37","author":"SJ Li","year":"2020","unstructured":"Li SJ, Hao J, Mao Y, Si YL (2020) Effects of the proteasome inhibitor bortezomib in combination with chemotherapy for the treatment of mantle cell lymphoma: a meta-analysis. Turk J Haematol 37(1):13\u201319","journal-title":"Turk J Haematol"},{"issue":"2","key":"1362_CR92","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00277-017-3173-9","volume":"97","author":"W Xu","year":"2018","unstructured":"Xu W, Sun X, Wang B, Guo H (2018) Pooled analysis of the reports of carfilzomib\/ixazomib combinations for relapsed\/refractory multiple myeloma. Ann Hematol 97(2):299\u2013307","journal-title":"Ann Hematol"},{"issue":"2","key":"1362_CR93","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/jbmr.3889","volume":"35","author":"H Wang","year":"2020","unstructured":"Wang H, Zhang H, Srinivasan V, Tao J, Sun W, Lin X et al (2020) Targeting bortezomib to bone increases its bone anabolic activity and reduces systemic adverse effects in mice. J Bone Miner Res 35(2):343\u2013356","journal-title":"J Bone Miner Res"},{"key":"1362_CR94","doi-asserted-by":"crossref","first-page":"172458","DOI":"10.1155\/2015\/172458","volume":"2015","author":"F Accardi","year":"2015","unstructured":"Accardi F, Toscani D, Bolzoni M, Dalla Palma B, Aversa F, Giuliani N (2015) Mechanism of action of bortezomib and the new proteasome inhibitors on myeloma cells and the bone microenvironment: impact on myeloma-induced alterations of bone remodeling. Biomed Res Int 2015:172458","journal-title":"Biomed Res Int"},{"key":"1362_CR95","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.bone.2016.02.019","volume":"86","author":"M Zangari","year":"2016","unstructured":"Zangari M, Suva LJ (2016) The effects of proteasome inhibitors on bone remodeling in multiple myeloma. Bone 86:131\u2013138","journal-title":"Bone"},{"issue":"2","key":"1362_CR96","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3390\/cancers12020323","volume":"12","author":"D Tibullo","year":"2020","unstructured":"Tibullo D, Longo A, Vicario N, Romano A, Barbato A, Di Rosa M et al (2020) Ixazomib improves bone remodeling and counteracts sonic hedgehog signaling inhibition mediated by myeloma cells. Cancers (Basel) 12(2):323","journal-title":"Cancers (Basel)"},{"issue":"7","key":"1362_CR97","doi-asserted-by":"crossref","first-page":"e0253722","DOI":"10.1371\/journal.pone.0253722","volume":"16","author":"S Rath","year":"2021","unstructured":"Rath S, Elamarthi P, Parab P, Gulia S, Nandhana R, Mokal S et al (2021) Efficacy and safety of palbociclib and ribociclib in patients with estrogen and\/or progesterone receptor positive, HER2 receptor negative metastatic breast cancer in routine clinical practice. PLoS ONE 16(7):e0253722","journal-title":"PLoS ONE"},{"issue":"25","key":"1362_CR98","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P et al (2021) Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med 384(25):2394\u20132405","journal-title":"N Engl J Med"},{"issue":"1","key":"1362_CR99","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.clbc.2020.09.014","volume":"21","author":"A Chan","year":"2021","unstructured":"Chan A, Moy B, Mansi J, Ejlertsen B, Holmes FA, Chia S et al (2021) Final efficacy results of neratinib in her2-positive hormone receptor-positive early-stage breast cancer from the phase III extenet trial. Clin Breast Cancer 21(1):80-91.e7","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"1362_CR100","doi-asserted-by":"crossref","first-page":"R247","DOI":"10.1530\/ERC-12-0400","volume":"21","author":"JO Alem\u00e1n","year":"2014","unstructured":"Alem\u00e1n JO, Farooki A, Girotra M (2014) Effects of tyrosine kinase inhibition on bone metabolism: untargeted consequences of targeted therapies. Endocr.-Related Cancer 21(3):R247\u2013R259","journal-title":"Endocr.-Related Cancer"},{"issue":"2","key":"1362_CR101","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.bone.2011.04.014","volume":"49","author":"S O\u2019Sullivan","year":"2011","unstructured":"O\u2019Sullivan S, Lin JM, Watson M, Callon K, Tong PC, Naot D et al (2011) The skeletal effects of the tyrosine kinase inhibitor nilotinib. Bone 49(2):281\u2013289","journal-title":"Bone"},{"issue":"4","key":"1362_CR102","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1210\/jc.2008-2324","volume":"94","author":"S O\u2019Sullivan","year":"2009","unstructured":"O\u2019Sullivan S, Horne A, Wattie D, Porteous F, Callon K, Gamble G et al (2009) Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib. J Clin Endocrinol Metab 94(4):1131\u20131136","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1362_CR103","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.tripleo.2011.06.023","volume":"113","author":"Y Fleissig","year":"2012","unstructured":"Fleissig Y, Regev E, Lehman H (2012) Sunitinib related osteonecrosis of jaw: a case report. Oral Surg, Oral Med, Oral Pathol and Oral Radiol 113(3):e1-3","journal-title":"Oral Surg, Oral Med, Oral Pathol and Oral Radiol"},{"key":"1362_CR104","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.5301\/tj.5000504","volume":"102","author":"F Garuti","year":"2016","unstructured":"Garuti F, Camelli V, Spinardi L, Bucci L, Trevisani F (2016) Osteonecrosis of THE JAW DURING SORAFENIB THERAPY FOR HEPATOCELLULAR CARCINOma. Tumori 102:S69-70","journal-title":"Tumori"},{"issue":"8","key":"1362_CR105","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.3109\/10428194.2013.772608","volume":"54","author":"E Terpos","year":"2013","unstructured":"Terpos E, Apperley J, Milojkovic D (2013) Imatinib and chronic myeloid leukemia: close to the bone. Leuk Lymphoma 54(8):1581\u20131582","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"1362_CR106","doi-asserted-by":"crossref","first-page":"e812","DOI":"10.1097\/MAO.0000000000002344","volume":"40","author":"F Canzano","year":"2019","unstructured":"Canzano F, Di Lella F, Manuguerra R, Vincenti V (2019) Osteonecrosis of the external auditory canal associated with oral sorafenib therapy: sorafenib and temporal bone osteonecrosis. Otol & Neurotol 40(8):e812","journal-title":"Otol & Neurotol"},{"issue":"8","key":"1362_CR107","doi-asserted-by":"crossref","first-page":"e822","DOI":"10.1097\/MPH.0000000000001595","volume":"42","author":"T Hosokawa","year":"2020","unstructured":"Hosokawa T, Hara T, Arakawa Y, Oguma E, Yamada Y (2020) Periosteal reaction possibly induced by pazopanib: a case report and literature review. J Pediatr Hematol Oncol 42(8):e822","journal-title":"J Pediatr Hematol Oncol"},{"issue":"12","key":"1362_CR108","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1002\/pbc.24674","volume":"60","author":"M Ramzan","year":"2013","unstructured":"Ramzan M, Verma R, Chopra YR, Yadav SP (2013) Post-fracture excessive callus formation in a child on imatinib therapy. Pediatr Blood Cancer 60(12):2087\u20132088","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"1362_CR109","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/ijc.26034","volume":"130","author":"S Maita","year":"2012","unstructured":"Maita S, Yuasa T, Tsuchiya N, Mitobe Y, Narita S, Horikawa Y et al (2012) Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function. Int J Cancer 130(3):677\u2013684","journal-title":"Int J Cancer"},{"issue":"5","key":"1362_CR110","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/JPER.18-0334","volume":"90","author":"NK Pokhrel","year":"2019","unstructured":"Pokhrel NK, Kim YG, Kim HJ, Kim HJ, Lee JH, Choi SY et al (2019) A novel Bruton\u2019s tyrosine kinase inhibitor, acalabrutinib, suppresses osteoclast differentiation and Porphyromonas gingivalis lipopolysaccharide-induced alveolar bone resorption. J Periodontol 90(5):546\u2013554","journal-title":"J Periodontol"},{"issue":"3","key":"1362_CR111","doi-asserted-by":"crossref","first-page":"150","DOI":"10.5483\/BMBRep.2017.50.3.223","volume":"50","author":"HJ Ihn","year":"2017","unstructured":"Ihn HJ, Kim JA, Bae YC, Shin HI, Baek MC, Park EK (2017) Afatinib ameliorates osteoclast differentiation and function through downregulation of RANK signaling pathways. BMB Rep 50(3):150\u2013155","journal-title":"BMB Rep"},{"issue":"3","key":"1362_CR112","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/annonc\/mdr261","volume":"23","author":"M Campone","year":"2012","unstructured":"Campone M, Bondarenko I, Brincat S, Hotko Y, Munster PN, Chmielowska E et al (2012) Phase II study of single-agent bosutinib, a Src\/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. Ann Oncol 23(3):610\u2013617","journal-title":"Ann Oncol"},{"issue":"3","key":"1362_CR113","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.3324\/haematol.2012.067447","volume":"98","author":"F Giona","year":"2013","unstructured":"Giona F, Mariani S, Gnessi L, Moleti ML, Rea M, De Vellis A et al (2013) Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty. Haematologica 98(3):e25\u2013e27","journal-title":"Haematologica"},{"issue":"Suppl","key":"1362_CR114","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/j.clml.2016.02.027","volume":"16","author":"D Hoehn","year":"2016","unstructured":"Hoehn D, Cortes JE, Medeiros LJ, Jabbour EJ, Hidalgo JE, Kanagal-Shamanna R et al (2016) Multiparameter analysis of the \u201cOff-Target Effects\u201d of dasatinib on bone homeostasis in patients with newly diagnosed chronic myelogenous leukemia. Clin Lymphoma Myeloma Leuk 16(Suppl):S86-92","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"1362_CR115","doi-asserted-by":"crossref","first-page":"e78881","DOI":"10.1371\/journal.pone.0078881","volume":"8","author":"HM Nguyen","year":"2013","unstructured":"Nguyen HM, Ruppender N, Zhang X, Brown LG, Gross TS, Morrissey C et al (2013) Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling. PLoS ONE 8(10):e78881","journal-title":"PLoS ONE"},{"issue":"1","key":"1362_CR116","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s40425-018-0417-8","volume":"6","author":"KF Moseley","year":"2018","unstructured":"Moseley KF, Naidoo J, Bingham CO, Carducci MA, Forde PM, Gibney GT et al (2018) Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series. J Immunother Cancer 6(1):104","journal-title":"J Immunother Cancer"},{"issue":"4","key":"1362_CR117","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00198-023-06690-1","volume":"34","author":"C Ye","year":"2023","unstructured":"Ye C, Lee K, Leslie WD, Lin M, Walker J, Kolinsky M (2023) Fracture rate increases after immune checkpoint inhibitor treatment: a potential new immune related adverse event. Osteoporos Int 34(4):735\u2013740","journal-title":"Osteoporos Int"},{"key":"1362_CR118","unstructured":"Johnson, Rachel. (2023) PD-1 blockade disrupts bone microarchitecture and compromises bone strength in breast cancer bone metastasis. Vancouver, ASBMR meeting."},{"issue":"9","key":"1362_CR119","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/jnci\/djt026","volume":"105","author":"M Gnant","year":"2013","unstructured":"Gnant M, Baselga J, Rugo HS, Noguchi S, Burris HA, Piccart M et al (2013) Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. J Natl Cancer Inst 105(9):654\u2013663","journal-title":"J Natl Cancer Inst"},{"key":"1362_CR120","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13058-017-0885-7","volume":"19","author":"AJ Browne","year":"2017","unstructured":"Browne AJ, Kubasch ML, G\u00f6bel A, Hadji P, Chen D, Rauner M et al (2017) Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer. Breast Cancer Res 19:92","journal-title":"Breast Cancer Res"},{"issue":"6","key":"1362_CR121","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.joca.2019.01.009","volume":"27","author":"Y Kakiuchi","year":"2019","unstructured":"Kakiuchi Y, Yurube T, Kakutani K, Takada T, Ito M, Takeoka Y et al (2019) Pharmacological inhibition of mTORC1 but not mTORC2 protects against human disc cellular apoptosis, senescence, and extracellular matrix catabolism through Akt and autophagy induction. Osteoarthr Cartil 27(6):965\u2013976","journal-title":"Osteoarthr Cartil"},{"issue":"1","key":"1362_CR122","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.2146\/ajhp170269","volume":"75","author":"RL McDevitt","year":"2018","unstructured":"McDevitt RL, Quinlan C, Hersberger K, Sahai V (2018) Bone marrow edema associated with everolimus. Am JHealth-Sys Pharm 75(1):e23\u2013e27","journal-title":"Am JHealth-Sys Pharm"},{"issue":"6","key":"1362_CR123","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/mpo.1136","volume":"36","author":"G Holzer","year":"2001","unstructured":"Holzer G, Obermair A, Koschat M, Preyer O, Kotz R, Trieb K (2001) Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with malignant bone tumors. Med Pediatr Oncol 36(6):601\u2013604","journal-title":"Med Pediatr Oncol"},{"issue":"2","key":"1362_CR124","doi-asserted-by":"crossref","first-page":"335","DOI":"10.4103\/jcrt.JCRT_11_20","volume":"16","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Dong G, Wang F, Ding W (2020) Correlation between the changes of serum COX 2, APE1, VEGF, TGF-\u03b2 and TSGF levels and prognosis in patients with osteosarcoma before and after treatment. J Cancer Res Ther 16(2):335\u2013342","journal-title":"J Cancer Res Ther"},{"issue":"135","key":"1362_CR125","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/ijc.28787","volume":"6","author":"R Bachelier","year":"2014","unstructured":"Bachelier R, Confavreux C, Peyruchaud O, Croset M, Goehrig D, Pluijm G (2014) Combination of anti-angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis. Int J Cancer 6(135):1319\u20131329","journal-title":"Int J Cancer"},{"key":"1362_CR126","doi-asserted-by":"crossref","unstructured":"Bettini G, Blandamura S, Saia G, Bedogni A. Bevacizumab-related osteonecrosis of the mandible is a self-limiting disease process. BMJ Case Rep. 2012;","DOI":"10.1136\/bcr-2012-007284"},{"issue":"17","key":"1362_CR127","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10006-012-0379-9","volume":"4","author":"D Pakosch","year":"2013","unstructured":"Pakosch D, Papadimas D, Munding J, Kawa D, Kriwalsky M (2013) Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab. Oral Maxillofac Surg 4(17):303\u2013306","journal-title":"Oral Maxillofac Surg"},{"issue":"2","key":"1362_CR128","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0014-5793(00)01520-9","volume":"473","author":"M Nakagawa","year":"2000","unstructured":"Nakagawa M, Kaneda T, Arakawa T, Morita S, Sato T, Yomada T et al (2000) Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett 473(2):161\u2013164","journal-title":"FEBS Lett"},{"issue":"7","key":"1362_CR129","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.exphem.2014.03.005","volume":"42","author":"A Bolomsky","year":"2014","unstructured":"Bolomsky A, Schreder M, Mei\u00dfner T, Hose D, Ludwig H, Pfeifer S et al (2014) Immunomodulatory drugs thalidomide and lenalidomide affect osteoblast differentiation of human bone marrow stromal cells in\u00a0vitro. Exp Hematol 42(7):516\u2013525","journal-title":"Exp Hematol"},{"issue":"8","key":"1362_CR130","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1182\/blood-2005-08-3450","volume":"107","author":"G Anderson","year":"2006","unstructured":"Anderson G, Gries M, Kurihara N, Honjo T, Anderson J, Donnenberg V et al (2006) Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 107(8):3098\u20133105","journal-title":"Blood"},{"issue":"4","key":"1362_CR131","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.exphem.2012.11.005","volume":"41","author":"M Bolzoni","year":"2013","unstructured":"Bolzoni M, Storti P, Bonomini S, Todoerti K, Guasco D, Toscani D et al (2013) Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL\/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules. Exp Hematol 41(4):387-397.e1","journal-title":"Exp Hematol"},{"issue":"10","key":"1362_CR132","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/leu.2008.174","volume":"22","author":"I Breitkreutz","year":"2008","unstructured":"Breitkreutz I, Raab MS, Vallet S, Hideshima T, Raje N, Mitsiades C et al (2008) Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 22(10):1925\u20131932","journal-title":"Leukemia"},{"key":"1362_CR133","doi-asserted-by":"crossref","first-page":"iv79","DOI":"10.1093\/annonc\/mdy310","volume":"29","author":"PG Casali","year":"2018","unstructured":"Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R et al (2018) Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29:iv79-95","journal-title":"Ann Oncol"},{"issue":"27","key":"1362_CR134","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1200\/JCO.2014.59.5256","volume":"33","author":"N Gaspar","year":"2015","unstructured":"Gaspar N, Hawkins DS, Dirksen U, Lewis IJ, Ferrari S, Le Deley MC et al (2015) Ewing sarcoma: current management and future approaches through collaboration. J Clin Oncol 33(27):3036\u20133046","journal-title":"J Clin Oncol"},{"issue":"4","key":"1362_CR135","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1097\/MPH.0b013e318279b1fb","volume":"35","author":"R Hayward","year":"2013","unstructured":"Hayward R, Iwaniec UT, Turner RT, Lien CY, Jensen BT, Hydock DS et al (2013) Voluntary wheel running in growing rats does not protect against doxorubicin-induced osteopenia. J Pediatr Hematol Oncol 35(4):e144-148","journal-title":"J Pediatr Hematol Oncol"},{"issue":"11","key":"1362_CR136","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1097\/CORR.0000000000001842","volume":"479","author":"G Holzer","year":"2021","unstructured":"Holzer G, Hobusch G, Hansen S, Fischer L, Patsch JM (2021) Is There an Association Between Bone Microarchitecture and Fracture in Patients who were Treated for High-grade Osteosarcoma? A controlled study at long-term follow-up using high-resolution peripheral quantitative CT. Clin Orthop Relat Res 479(11):2493\u20132501","journal-title":"Clin Orthop Relat Res"},{"issue":"10","key":"1362_CR137","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1007\/s11999-012-2448-7","volume":"470","author":"UM Pirker-Fr\u00fchauf","year":"2012","unstructured":"Pirker-Fr\u00fchauf UM, Friesenbichler J, Urban EC, Obermayer-Pietsch B, Leithner A (2012) Osteoporosis in children and young adults: a late effect after chemotherapy for bone sarcoma. Clin Orthop Relat Res 470(10):2874\u20132885","journal-title":"Clin Orthop Relat Res"},{"key":"1362_CR138","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bone.2015.04.047","volume":"78","author":"D Song","year":"2015","unstructured":"Song D, Meng T, Xu W, Hou T, Lin Z, Yin H et al (2015) 5-Fluoruracil blocked giant cell tumor progression by suppressing osteoclastogenesis through NF-kappaB signals and blocking angiogenesis. Bone 78:46\u201354","journal-title":"Bone"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-025-01362-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-025-01362-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-025-01362-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T13:22:15Z","timestamp":1766755335000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-025-01362-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":138,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1362"],"URL":"https:\/\/doi.org\/10.1007\/s00223-025-01362-0","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"30 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The following authors MT, MP, EB, EB, TV, GH, GEHF, MLB and RR declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare the following conflicts of interests: Research grants: PH (Stada), PE (Amgen, Alexion, Sanofi) and CC (Amgen, MSD avenir). Conferences: PH (UCB), PE (Amgen, Kyowa-Kirin, Alexion), DK (Amgen, Radius Pharma), JJB (Amgen), CC (Amgen, BMS, Lilly, MSD, Theramex).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"54"}}